Evommune, Inc.
$27.97
▲
5.8%
2026-04-21 06:44:01
www.evommune.com
NYQ: EVMN
Explore Evommune, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$988.7 M
Current Price
$27.97
52W High / Low
$33.2 / $13.88
Stock P/E
—
Book Value
$6.52
Dividend Yield
—
ROCE
-39.16%
ROE
-54.42%
Face Value
—
EPS
$-11.22
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
48
Beta
—
Debt / Equity
1
Current Ratio
8.57
Quick Ratio
8.57
Forward P/E
-7.6
Price / Sales
70.68
Enterprise Value
$771.69 M
EV / EBITDA
-9.69
EV / Revenue
59.36
Rating
Strong Buy
Target Price
$51
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Enanta Pharmaceuticals, Inc. | $13.78 | — | $409.17 M | — | -36.76% | -60.01% | $17.15 / $4.83 | $4.36 |
| 2. | MediWound Ltd. | $17.35 | — | $226.34 M | — | -41.75% | -63.86% | $22.5 / $14.9 | $3.4 |
| 3. | Tectonic Therapeutic, Inc. | $28.76 | — | $554.1 M | — | -33.43% | -37.82% | $36.03 / $14.39 | $13.41 |
| 4. | Neumora Therapeutics, Inc. | $2.19 | — | $391.39 M | — | -152.06% | -1.21% | $3.65 / $0.61 | $0.6 |
| 5. | Imunon, Inc. | $3.1 | — | $12.36 M | — | -191.16% | -2.56% | $41.22 / $2.52 | $2.42 |
| 6. | Nuvation Bio Inc. | $5.12 | — | $1.77 B | — | -41.57% | -53.18% | $9.75 / $1.57 | $0.88 |
| 7. | eXoZymes, Inc. | $10.66 | — | $89.88 M | — | -220.6% | -1.33% | $18.4 / $7.08 | $0.4 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|
| Sales | 0 M | 10 M | 0 M | 0 M |
| Operating Profit | -29.72 M | -13.33 M | -21.45 M | -16.52 M |
| Net Profit | -28.27 M | -12.47 M | -20.73 M | -15.92 M |
| EPS in Rs | -0.78 | -0.35 | -0.58 | -0.44 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | |
|---|---|---|
| Sales | 13 M | — |
| Operating Profit | -81.07 M | — |
| Net Profit | -68.87 M | — |
| EPS in Rs | -1.91 | -4.27 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | |
|---|---|---|
| Total Assets | 224.95 M | — |
| Total Liabilities | 19.38 M | — |
| Equity | 205.57 M | — |
| Current Assets | 153.48 M | — |
| Current Liabilities | 17.91 M | — |
Cash Flow
Last available yearly cash flow history
| 2025 | |
|---|---|
| Operating CF | -76.44 M |
| Investing CF | -115.31 M |
| Financing CF | 220.76 M |
| Free CF | -76.68 M |
| Capex | -0.23 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | |
|---|---|---|
| Revenue Growth % | — | — |
| Earnings Growth % | — | — |
| Profit Margin % | -529.77% | — |
| Operating Margin % | -623.62% | — |
| Gross Margin % | — | — |
| EBITDA Margin % | -612.94% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.